CClinicalTrials.gg
Sign In
RecruitingNCT07634666URO-MINSUpdated Jul 22, 2026

Prediction of Myocardial Injury After Non-Cardiac Surgery in Urologic Cancer Patients

An observational study in Myocardial Injury After Non-cardiac Surgery, Urologic Cancer and Major Adverse Cardiovascular Events (MACE), sponsored by Korea University Anam Hospital. Recruiting at 1 site in South Korea. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Korea University Anam Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
60 Years and older
Sex
All
01

Study summary

This prospective multicenter observational study aims to evaluate the predictive value of artificial intelligence-based analysis of preoperative 12-lead electrocardiography for myocardial injury after non-cardiac surgery (MINS) and major adverse cardiovascular events (MACE) within 30 days after surgery in patients undergoing non-cardiac surgery for urologic cancer.

Read the detailed description

Myocardial injury after non-cardiac surgery (MINS) is associated with increased postoperative morbidity and mortality. Patients with urologic cancer undergoing major non-cardiac surgery may be at increased risk for perioperative cardiovascular complications. Early identification of patients at high risk for postoperative myocardial injury and adverse cardiovascular events may improve perioperative risk stratification and clinical management.

This prospective multicenter observational study aims to evaluate the predictive value of artificial intelligence-based analysis of preoperative 12-lead electrocardiography for postoperative myocardial injury after non-cardiac surgery (MINS) and major adverse cardiovascular events (MACE) within 30 days after surgery in patients undergoing non-cardiac surgery for urologic cancer.

Clinical characteristics, perioperative variables, electrocardiographic data, laboratory findings, and postoperative outcomes will be prospectively collected and analyzed to identify predictors of postoperative cardiovascular complications.

02

Conditions studied

  • Myocardial Injury After Non-cardiac Surgery
  • Urologic Cancer
  • Major Adverse Cardiovascular Events (MACE)

Browse trials for

Keywords

  • Artificial Intelligence
  • Electrocardiography
  • Myocardial Injury After Non-cardiac Surgery
  • Major Adverse Cardiovascular Events
  • Perioperative Cardiovascular Risk
  • Urologic Cancer
03

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 60 years or older scheduled for major non-cardiac surgery under general anesthesia due to urologic malignancy (e.g., radical prostatectomy, radical nephrectomy, partial nephrectomy) will be prospectively enrolled from participating centers. All eligible patients who provide informed consent and meet inclusion criteria will be followed for perioperative myocardial injury and 30-day cardiovascular outcomes.

Inclusion criteria

  • Age ≥ 60 years
  • Patients scheduled for major non-cardiac surgery under general anesthesia due to urologic cancer (e.g., radical prostatectomy, radical nephrectomy, partial nephrectomy)
  • Patients who undergo preoperative standard 12-lead electrocardiography
  • Patients classified as having intermediate or higher surgical risk
  • Patients who can be followed for at least 30 days postoperatively
  • Patients who voluntarily provide written informed consent to participate in this study

Exclusion criteria

Exclusion Criteria:

  • History of major adverse cardiovascular events (MACE) within 6 months prior to surgery
  • Inability to obtain essential clinical information required for study participation and follow-up
  • Patients who are not hospitalized after surgery
  • Individuals deemed inappropriate for participation in the study by the investigator due to legal or psychiatric reasons
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Urologic cancer patients undergoing major non-cardiac surgery

    Patients with urologic malignancy scheduled for major non-cardiac surgery will be prospectively enrolled and observed for perioperative myocardial injury and related outcomes.

    Other: No intervention assigned

Interventions

  • OtherNo intervention assigned

    This is a prospective observational study. No interventions are administered. Participants are followed for the development of myocardial injury after major non-cardiac surgery.

05

What researchers measure

Primary outcomes

  1. Number of Participants with Myocardial Injury After Non-Cardiac Surgery (MINS)

    Myocardial injury after non-cardiac surgery (MINS), defined as an elevation of fourth-generation cardiac troponin T measured on the day of surgery, postoperative day 1, and postoperative day 2 (within 3 days after surgery)

    Time frame: Intraoperative day and postoperative days 1-2 (within 3 days after surgery)

Secondary outcomes

  1. Number of Participants with 30-Day Major Adverse Cardiovascular Events (MACE)

    Composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke occurring within 30 days after surgery.

    Time frame: Within 30 days after surgery

06

Study locations

1 of 1 sites recruiting
  • Seoul St. Mary's Hospital, The Catholic University of Korea
    Seoul, 06591, South Korea
    Recruiting
07

References and documents

Publications

  • Xie X, Hu W, Fan X, Chen H, Tang M. Interactions Between Phosphorus, Zinc, and Iron Homeostasis in Nonmycorrhizal and Mycorrhizal Plants. Front Plant Sci. 2019 Sep 26;10:1172. doi: 10.3389/fpls.2019.01172. eCollection 2019. PubMed 31616454 ↗
  • Matsubara M, Muraki Y, Suzuki H, Hatano N, Muraki K. Critical amino acid residues regulating TRPA1 Zn2+ response: A comparative study across species. J Biol Chem. 2024 Jun;300(6):107302. doi: 10.1016/j.jbc.2024.107302. Epub 2024 Apr 18. PubMed 38642892 ↗
  • Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I, Geisler T, Hinterbuchner L, Ibanez B, Lenarczyk R, Mansmann UR, McGreavy P, Mueller C, Muneretto C, Niessner A, Potpara TS, Ristic A, Sade LE, Schirmer H, Schupke S, Sillesen H, Skulstad H, Torracca L, Tutarel O, Van Der Meer P, Wojakowski W, Zacharowski K; ESC Scientific Document Group. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022 Oct 14;43(39):3826-3924. doi: 10.1093/eurheartj/ehac270. No abstract available. PubMed 36017553 ↗
  • Zhong L, Yan K, Liu C, Xue J, Wu L, Yin F. Clinical reasoning: a young man with reversible paralysis, cerebral white matter lesions, and peripheral neuropathy. Neurology. 2012 Aug 21;79(8):e70-2. doi: 10.1212/WNL.0b013e3182661eca. No abstract available. PubMed 22915180 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared due to privacy concerns and institutional policies governing clinical data protection.

08

Registry details

Key details

Study ID
NCT07634666
Lead sponsor
Korea University Anam Hospital
Collaborators
The Catholic University of Korea, Keimyung University Dongsan Medical Center, Medical AI Co., Ltd
Responsible party
Cho, Dong Hyuck (Associate Professor, Korea University Anam Hospital) — Principal investigator
First posted
Jun 9, 2026
Start date
Jul 15, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 22, 2026

Study contacts

Dong Hyuck Cho, MD, PhD
Contact
why012@gmail.com
+82-2-920-5448
Jong-Chan Youn, MD, PhD
Contact
jong.chan.youn@gmail.com
+82-2-2258-6145
Dong Hyuck Cho, MD, PhD
principal investigator · Korea University Anam Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Urologic Neoplasms→

Other studies from this sponsor

Korea University Anam Hospital

Start the discussion